Genmab earnings boosted by Janssen collaboration

COPENHAGEN Wed May 7, 2014 12:48pm EDT

COPENHAGEN May 7 (Reuters) - Danish biotech company Genmab posted a 231 percent jump in first-quarter operating profit, mainly driven by increased revenue related to its collaboration with Janssen, a part of Johnson & Johnson, the company said on Wednesday.

The company, whose only drug on the market is blood cancer treatment Arzerra, lifted its operating profit to 96 million Danish crowns ($17.9 million) from 29 million a year before.

Revenue increased by 87 million crowns to 247 million crowns, mainly driven by a 119 million milestone payment received from Janssen in March..

The company kept its 2014 operating income outlook of between 140 million crowns and 210 million, having upgraded it earlier this month..

Genmab also expects 2014 operating expenses in a range of 600 million crowns to 650 million.

($1 = 5.3612 Danish Crowns) (Reporting by Stine Jacobsen; Editing by David Holmes)

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

California state worker Albert Jagow (L) goes over his retirement options with Calpers Retirement Program Specialist JeanAnn Kirkpatrick at the Calpers regional office in Sacramento, California October 21, 2009. Calpers, the largest U.S. public pension fund, manages retirement benefits for more than 1.6 million people, with assets comparable in value to the entire GDP of Israel. The Calpers investment portfolio had a historic drop in value, going from a peak of $250 billion in the fall of 2007 to $167 billion in March 2009, a loss of about a third during that period. It is now around $200 billion. REUTERS/Max Whittaker   (UNITED STATES) - RTXPWOZ

How to get out of debt

Financial adviser Eric Brotman offers strategies for cutting debt from student loans and elder care -- and how to avoid money woes in the first place.  Video